Tonix Pharmaceuticals

Gold Sponsor

Tonix is a NASDAQ - traded commercial stage biopharmaceutical company focused on developing novel therapeutics to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. Tonix’s lead infectious disease product candidate, TNX-801, is a live horsepox virus vaccine for percutaneous administration  in development to protect against smallpox and monkeypox. Tonix will continue work on this live virus vector technology as a platform for rapid response to new pathogens. TNX-1800 is our vaccine against SARS-CoV-2  and was selected to be part of Project NextGen, the NIH/NIAID program to develop next generation COVID vaccines.